中图分类号R956 文献标志码A 文章编号 1001-0408(2025)14-1765-05

    DOI 10.6039/j.issn.1001-0408.2025.14.13

    ABSTRACTOBJECTIVEToperformapharmacoeconomicevaluationofcamrelizumabcombinedwithchemotherapyinthe treatmentof cervical cancer in China.METHODSFrom the perspectiveof China'shealthcare system，a Markov model was constructedbasedonliteraturedataregarding the treatmentofcervical cancer with camrelizumabcombined with chemotherapy， where theincidenceofadversereactions wasobtainedthroughameta-analysis.The modelwasrunovera1O-year time horizon with a3-weekcyclelength.Costsincludeddirectcosts(e.g.drugcost，adverseeventreatmentcost).Utilityvalues werederivedfrom existing studies，and transition probabilities were calculated using literature data，with a discount rate of 5% ； the willingness-to-pay (WTP)thresholdwassetat3times China’s2024percapita grossdomestic product(GDP)，i.e.287247yuan/quality-adjusted life year(QALY).Cost-efectivenesswascomparedbetweencamrelizumabcombinedwithchemotherapyand monotherapy.One-way sensitivityanalysisandMonteCarlo simulation wereusedtoevaluate theimpactof parameter variationsonresults.RESULTS Comparedwithcamrelizumabmonotherapy ......